Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.

Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma. 2008 Jun; 8(3):166-70.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Costs and Cost Analysis
Cyclophosphamide
Disease-Free Survival
Doxorubicin
Female
Humans
Lymphoma, Follicular
Male
Models, Biological
Prednisone
Remission Induction
Rituximab
Survival Rate
United States
Vincristine

authors with profiles

Kit N. Simpson